BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-324 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-324\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06858813-2318@assetmemo.bio
DTSTAMP:20261121T005815Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:ABBV-324: Phase 1 readout est. (NCT06858813)
DESCRIPTION:ABBV-324\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y to Assess Adverse Events and Change in Disease Activity of Intravenously
  (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (H
 CC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)\nEstimated primary 
 completion: September 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/abbv-324#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06858813
URL:https://assetmemo.bio/drug/abbv-324#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
